Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 13/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20208549 | 0.78 | DYRK1A (0.59) | GRM5KDM4ENPC1ALDH1A1GAA | |
| SCHEMBL20209001 | 0.78 | SCN5A (0.52) | KDM4ENPC1ALDH1A1GAAMAPT | |
| SCHEMBL20203727 | 0.77 | SCN5A (0.64) | GRM5KDM4ENPC1ALDH1A1GAA | |
| SCHEMBL20190225 | 0.75 | SCN5A (0.50) | KDM4ENPC1ALDH1A1GAAMAPT | |
| SCHEMBL20190662 | 0.75 | SCN5A (0.47) | KDM4ENPC1ALDH1A1GAAMAPT | |
| SCHEMBL3265605 | 0.75 | MEN1 (0.47) | SCN5A | |
| SCHEMBL20208575 | 0.74 | SCN5A (0.45) | KDM4ENPC1ALDH1A1GAAMAPT | |
| SCHEMBL16215338 | 0.73 | GABBR2 (0.49) | SCN5A | |
| SCHEMBL23572498 | 0.72 | SCN5A (0.52) | GRM5KDM4ENPC1ALDH1A1GAA | |
| SCHEMBL20208519 | 0.72 | SCN5A (0.71) | KDM4ENPC1ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | GRM5 179/4885KDM4E 2066/4885NPC1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.